Blog
RSS FeedPosted by Michael Wonder on 20 Aug 2025
Health Canada approves dual immunotherapy Opdivo plus Yervoy for colorectal and liver cancers
19 August 2025 - Bristol Myers Squibb Canada today announced that Health Canada has approved Opdivo (nivolumab) in combination with ...
Posted by Michael Wonder on 20 Aug 2025
Health Canada approves Ozempic to reduce the risk of sustained eGFR decline, end stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
19 August 2025 - Novo Nordisk announced today that Ozempic (semaglutide injection) is now approved as the first and only ...
Posted by Michael Wonder on 19 Aug 2025
Pfizer Canada and BioNTech receive Health Canada approval of LP.8.1 variant adapted COVID-19 vaccine
18 August 2025 - LP.8.1 variant adapted COVID-19 vaccine Cominaty is now authorised in Canada for individuals 6 months of age ...
Posted by Michael Wonder on 19 Aug 2025
Iovance’s Amtagvi (lifileucel) receives Health Canada approval for advanced melanoma
18 August 2025 - Iovance Biotherapeutics today announced Health Canada has issued a Notice of Compliance with Conditions for Amtagvi ...
Posted by Michael Wonder on 19 Aug 2025
Valneva’s chikungunya vaccine Ixchiq now authorised in Canada for individuals aged 12 and plder
18 August 2025 - Valneva today announced that Health Canada has granted marketing authorisation for its single dose vaccine, Ixchiq, ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 14 Aug 2025
Health Canada approves Keytruda for patients with resectable locally advanced head & neck squamous cell carcinoma tumours that are PD-L1 (CPS) positive as neo-adjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without cisplatin then as monotherapy
13 August 2025 - Approval is based on KEYNOTE-689 Phase III clinical trial results. ...
Posted by Michael Wonder on 09 Aug 2025
Imfinzi approved in Canada as first and only peri-operative immunotherapy for muscle invasive bladder cancer
6 August 2025 - Health Canada has granted a Notice of Compliance for Imfinzi (durvalumab) for the treatment of patients ...
Posted by Michael Wonder on 09 Aug 2025
Health Canada has authorised CSL's Andembry (garadacimab) as once monthly treatment for hereditary angioedema
8 August 2025 - CSL today announced that Health Canada has granted a marketing authorisation for Andembry (garadacimab) for routine ...
Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have ...
Posted by Michael Wonder on 08 Aug 2025
Access to multiple sclerosis treatments inadequate in British Columbia
7 August 2025 - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis, is calling for the provincial ...
Posted by Michael Wonder on 06 Aug 2025
Kye Pharmaceuticals announces the approval of Dynavel XR (amphetamine extended release) tablets and oral suspension for the treatment of adults and children with ADHD
5 August 2025 - Kye Pharmaceuticals is pleased to announce the Health Canada approval (notice of compliance) for Dyanavel XR ...
Posted by Michael Wonder on 30 Jul 2025
Health Canada expands approval of Scemblix, making it an option for newly diagnosed and previously treated chronic myeloid leukaemia patients
30 July 2025 - Scemblix is first to show superior efficacy and a favourable safety and tolerability profile in a Phase ...
Posted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, ...
Posted by Michael Wonder on 30 Jul 2025
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx for hidradenitis suppurativa (
23 July 2025 - Following this important milestone, Cosentyx has been listed in Québec. ...